Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases - 07/06/21
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background |
Cutaneous reactions after messenger RNA (mRNA)-based COVID-19 vaccines have been reported but are not well characterized.
Objective |
To evaluate the morphology and timing of cutaneous reactions after mRNA COVID-19 vaccines.
Methods |
A provider-facing registry-based study collected cases of cutaneous manifestations after COVID-19 vaccination.
Results |
From December 2020 to February 2021, we recorded 414 cutaneous reactions to mRNA COVID-19 vaccines from Moderna (83%) and Pfizer (17%). Delayed large local reactions were most common, followed by local injection site reactions, urticarial eruptions, and morbilliform eruptions. Forty-three percent of patients with first-dose reactions experienced second-dose recurrence. Additional less common reactions included pernio/chilblains, cosmetic filler reactions, zoster, herpes simplex flares, and pityriasis rosea-like reactions.
Limitations |
Registry analysis does not measure incidence. Morphologic misclassification is possible.
Conclusions |
We report a spectrum of cutaneous reactions after mRNA COVID-19 vaccines. We observed some dermatologic reactions to Moderna and Pfizer vaccines that mimicked SARS-CoV-2 infection itself, such as pernio/chilblains. Most patients with first-dose reactions did not have a second-dose reaction and serious adverse events did not develop in any of the patients in the registry after the first or second dose. Our data support that cutaneous reactions to COVID-19 vaccination are generally minor and self-limited, and should not discourage vaccination.
Le texte complet de cet article est disponible en PDF.Key words : COVID-19, dermatology, Moderna, mRNA, Pfizer, public health, registry, SARS-CoV-2, vaccine, vaccine reaction, delayed hypersensitivity, delayed inflammatory reaction, zoster, shingles, delayed large local reaction, pityriasis rosea, local injection site reaction, erythromelalgia, urticaria, morbilliform, pernio, chilblains, vesicular, erythema multiforme, filler, vasculitis
Abbreviations used : IQR, mRNA
Plan
| Funding sources: COVID-19 registry support provided to Massachusetts General Hospital by the International League of Dermatological Societies for administration and maintenance and by the American Academy of Dermatology for in-kind administrative support. |
|
| IRB approval status: Exempt. The registry was reviewed by the Partners Healthcare (Massachusetts General Hospital) Institutional Review Board and was determined to not meet the definition of human subject research. |
Vol 85 - N° 1
P. 46-55 - juillet 2021 Retour au numéro
Article précédent
- Body site distribution of pediatric-onset morphea and association with extracutaneous manifestations
- Yvonne E. Chiu, Leonid Shmuylovich, Tina Kiguradze, Katelyn Anderson, Cathryn Sibbald, Megha Tollefson, Elaine Kunzler, Wynnis L. Tom, Kelsie Bond, Regina-Celeste Ahmad, Maria Teresa Garcia-Romero, Mahwish Irfan, Kaitlyn Kollman, Raegan Hunt, Sarah L. Stein, Lisa Arkin, Vivian Wong, Elena Pope, Heidi Jacobe, Heather A. Brandling-Bennett, Kelly M. Cordoro, Lionel Bercovitch, Stephanie M. Rangel, Xuerong Liu, Aniko Szabo, Amy S. Paller
- Metformin is associated with decreased risk of basal cell carcinoma: A whole-population case-control study from Iceland
- Jonas A. Adalsteinsson, Sonal Muzumdar, Reid Waldman, Rong Wu, Désirée Ratner, Hao Feng, Jonathan Ungar, Jonathan I. Silverberg, Gudridur H. Olafsdottir, Arni Kjalar Kristjansson, Laufey Tryggvadottir, Jon Gunnlaugur Jonasson
Bienvenue sur EM-consulte, la référence des professionnels de santé.